Cystic Fibrosis Foundation invests up to $24 million in Prime Medicine to advance gene editing therapy for cystic fibrosis.
Amount Raised
$24 Million
Round Type
Funding Round
CambridgeBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
The Cystic Fibrosis Foundation has announced an investment of up to $24 million in Prime Medicine for the development of a gene editing therapy targeting cystic fibrosis. This funding will support preclinical research on the G542X mutation, which currently has no available therapies. The company is exploring gene editing technology for potential treatments. This investment builds on prior support aimed at demonstrating the versatility of prime editing.
Quick answer
Prime Medicine raised $24 Million in a Funding Round round, dated July 16, 2025. Investors: Cystic Fibrosis Foundation. Prime Medicine is based in Cambridge, Massachusetts, United States.
- How much did Prime Medicine raise?
- Prime Medicine raised $24 Million in a Funding Round round on July 16, 2025.
- Who invested in Prime Medicine?
- Cystic Fibrosis Foundation is named as investors in this round.
- What does Prime Medicine do?
- Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients.
- Where is Prime Medicine based and how big is it?
- Prime Medicine is based in Cambridge, Massachusetts, United States. Fundz records about 205 employees.
- Who are the decision-makers at Prime Medicine?
- Fundz holds 2 contacts at Prime Medicine, including the Advisor. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Prime Medicine that raised within 45 days of this round, from Fundz verified event records.
- Immuneering raised $25M on August 26, 2025.
- Calidi Biotherapeutics raised $6.9M (Post-IPO Equity) on August 21, 2025.
- QurAlis raised $20M on August 21, 2025.
- CILA Therapeutics raised an undisclosed amount (Grant) on August 15, 2025.
- Eyestem raised $10M (Series B) on August 11, 2025.
- Altera Biosciences raised $1.6M (Pre-Seed) on August 7, 2025.
Who to call at Prime Medicine, and when
A new round usually means Prime Medicine is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Prime Medicine raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Prime Medicine, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Prime Medicine. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Prime Medicine raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Prime Medicine raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.